This content is not available in your region

Vaccines and Genzyme help Sanofi keep promise of return to growth

Vaccines and Genzyme help Sanofi keep promise of return to growth
FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau   -   Copyright  CHARLES PLATIAU(Reuters)
Text size Aa Aa

By Matthias Blamont

PARIS (Reuters) – Sanofi <SASY.PA> narrowed its 2018 profit target for the second time this year after it posted higher-than-expected third-quarter profits, helped by robust sales growth at its key vaccines unit and its rare diseases Genzyme division.

The French drugmaker, hurt by declining diabetes sales and a struggle to refill its pipeline sufficiently in recent years, said it was now expecting earnings per share growth this year of 4 to 5 percent, up from a previous 3-5 percent target range.

Third-quarter business net income rose by 10.3 percent at constant exchange rates to 2.3 billion euros ($2.61 billion)while revenues advanced 6.3 percent to 9.4 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting a business net income of 2.14 billion euros on revenues of 9.3 billion.

Sales at Genzyme surged 36.1 percent to 1.9 billion euros. Vaccines revenue, hit during the second quarter by the supply constraint of a combination infant vaccine in China, rose 8.2 percent.

Diabetes and cardiovascular sales, however, fell 12.1 percent.

($1 = 0.8818 euros)

(Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.